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Abstract 
A novel canine muscular dystrophy in Landseer dogs was observed. We had access to five affected dogs 
from two litters. The clinical signs started at a few weeks of age and the severe progressive muscle 
weakness led to euthanasia between 5 and 15 months of age. The pedigrees of the affected dogs suggested a 
monogenic autosomal recessive inheritance of the trait. Linkage and homozygosity mapping indicated two 
potential genome segments for the causative variant on chromosomes 10 and 31 harboring a total of 4.8 Mb 
of DNA or 0.2% of the canine genome. Using the illumina sequencing technology we obtained a whole 
genome sequence from one affected Landseer. Variants were called with respect to the dog reference 
genome and compared to the genetic variants of 170 control dogs from other breeds. The affected Landseer 
dog was homozygous for a single private non-synonymous variant in the critical intervals, a nonsense 
variant in the COL6A1 gene (Chr31:39,303,964G>T; COL6A1:c.289G>T; p.E97*). Genotypes at this 
variant showed perfect concordance with the muscular dystrophy phenotype in all five cases and more than 
one thousand control dogs. Variants in the human COL6A1 gene cause Bethlem myopathy or Ullrich 
congenital muscular dystrophy. We therefore conclude that the identified canine COL6A1 variant is most 
likely causative for the observed muscular dystrophy in Landseer dogs. Based on the nature of the genetic 
variant in Landseer dogs and their severe clinical phenotype these dogs represent a model for human Ullrich 
congenital muscular dystrophy. 
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Introduction 
Muscular dystrophies are a heterogeneous group of inherited, degenerative disorders characterized by 
progressive muscular dysfunction (Flanigan 2012). Duchenne muscular dystrophy caused by variants in the 
X-chromosomal DMD gene and a complete loss of function of dystrophin is the text book representative for 
these entities (Koenig et al. 1987). However, although many of the muscular dystrophies are due to single 
gene defects, there is considerable variance in the phenotype (age of onset, severity and localization of 
clinical symptoms, rate of progression, etc.). This complexity arises from the fact that many genes are 
required for the structural integrity and proper function of skeletal muscle and that different genetic variants 
within a given gene can lead to quite distinct phenotypes. This again can be seen with the DMD gene: 
Variants that lead to a complete loss of function cause the severe Duchenne muscular dystrophy whereas 
variants that only partially affect dystrophin function result in the milder Becker muscular dystrophy (Hart 
et al. 1987; Koenig et al. 1989). The dystrophin protein interacts with many other skeletal muscle proteins 
and variants in genes encoding these other dystrophin-associated proteins can lead to very similar clinical 
phenotypes. 
Another group of muscular dystrophies with a much less well understood pathophysiology are the 
collagen VI myopathies. Collagen VI is a ubiquitously expressed extracellular matrix protein, composed of 
two chains of 140-150 kDa each, named alpha1(VI) and alpha2(VI), and one larger chain of 240-300 kDa 
named alpha3(VI) (Furthmayr et al. 1983). The three chains fold together into a triple-helical collagen VI 
molecule (monomer) that further assembles into dimers and tetramers. The tetramers are secreted into the 
extracellular space where they form collagen VI beaded microfibrils. In muscle, the microfibrillar network 
of collagen VI surrounds the basement membrane of fibers, binding components of the extracellular matrix 
and transferring mechanical and biochemical signals from the extracellular matrix to the muscle cell (De 
Palma et al. 2014). The three subunits of collagen VI are encoded by the COL6A1, COL6A2, and COL6A3 
genes. Variants in any of these genes can cause the severe Ullrich muscular dystrophy or the much milder 
Bethlem myopathy (Jöbsis et al. 1996; Camacho Vanegas et al. 2001). Many different variants have been 
identified in human patients and it is becoming increasingly clear that the phenotypic spectrum of these 
collagen VI myopathies is almost continuous depending on the specific genetic variants (Briñas et al. 2010). 
A complete list of all known functional human variants in the collagen VI genes is compiled at the Leiden 
Muscular Dystrophy pages (http://www.dmd.nl/). 
Dogs have been recognized as valuable models for many human hereditary diseases and the OMIA database 
currently lists ~350 potential canine models for human diseases. In roughly 200 of these, the causative 
genetic defect is known (Nicholas and Hobbs 2014; http://omia.angis.org.au/home/). Different muscular 
dystrophies have also been described in dogs. Golden Retrievers with a Duchenne-like muscular dystrophy 
due to a DMD variant are an extremely valuable animal model as Dmd mutant mice do not recapitulate the 
severe human (and canine) phenotypes (Cooper et al. 1988; Valentine et al. 1988; Valentine et al. 1992). 
Many other cases of muscular dystrophies in dogs and other companion animals have been reported. 
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Recently, the case of a myopathic Labrador Retriever was reported that showed greatly reduced or absent 
sarcolemmal collagen VI expression (Marioni-Henry et al. 2014). Collagen VI expression in this dog was 
still detectable by antibody staining in the endomysium. The clinical phenotype of this Labrador Retriever 
resembled an intermediate severity when compared with human Bethlem myopathy or Ullrich congenital 
muscular dystrophy. As the genetic defect in this Labrador Retriever is not known, it remains to be 
determined whether this represents a primary collagen VI defect or whether the reduction in collagen VI is a 
secondary effect of some other genetic lesion. Therefore, without the conclusive identification of the 
underlying causative genetic defect the value of these reports for our basic understanding of muscle function 
and a comparative analysis with respect to the human diseases remains limited. 
In this report, we describe a novel canine muscular dystrophy, which occurred in Landseer dogs. We also 
provide an initial limited characterization of the clinical and histopathological phenotype. The main focus of 
this study is on the identification of the presumed causative genetic defect by a positional cloning approach 
in combination with whole genome sequencing of an affected dog. 
 
Results 
Clinical presentation and laboratory findings 
We investigated a litter of 7 Landseer dogs. Two male and two female puppies were affected by progressive 
muscle weakness. One male puppy had been euthanized due to severe clinical signs in the first weeks of life 
without any ancillary diagnostic tests or necropsy. We examined the remaining 3 affected littermates, which 
were presented because of reluctance to move and prolonged sleeping episodes compared to their 3 normal 
siblings during the first few weeks of life. 
The male and the two female cases were clinically and neurologically examined at 14 and 18 weeks of age. 
No abnormalities were found on general physical examination of the male dog. On neurological evaluation, 
the male affected dog was mentally alert but only able to ambulate for a few steps before lying down. He 
had a short strided gait in the thoracic and pelvic limbs and while standing his back was arched and the 
pelvic limbs were placed under the abdomen. Stifle and tarsal joints were kept in a slightly flexed position. 
On palpation, the muscles of the limbs seemed to be atrophied and the articulations of elbow, carpus, hip 
and tarsus had a decreased range of motion. Manipulation of the joints seemed to be painful for the dog. 
Spinal reflexes and proprioceptive testing was normal, as was the remainder of the neurological 
examination. Both female dogs were examined and were found to be affected in different degrees of 
severity. While the clinical and neurological status of one female dog was comparable to those of the male 
dog, the second female was non-ambulatory and had difficulties with swallowing, regurgitation and 
salivation. This dog had an elevated body temperature of 39.6 °C and auscultation of the lungs revealed 
harsh sounds. Neurologically, the gag reflex was reduced but no other cranial nerve abnormalities were 
detected. Compared to her littermates, the muscles of this dog were more profoundly atrophied. The 
remainder of the neurological tests did not differ from those of her littermates. 
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In all affected dogs the creatine kinase activity (CK) was elevated (422, 935, 1149 IU/l; reference values: 
51-191 IU/l). Hematology of the more severely affected female revealed an elevated leukocyte cell count 
whereas it was normal in the other dogs. Urinalysis was normal in all dogs. Serology for Neospora canis and 
Toxoplasma gondii was tested in 2 dogs and results came back negative. 
Thoracic radiographs revealed generalized megaoesophagus and aspiration pneumonia in the severely 
affected female. In the other two dogs, radiographs did not show evidence of esophageal, lung or cardiac 
pathology. Radiographic examination of the hips, stifle, elbow and carpal articulation did not reveal any 
degenerative findings or conformational abnormalities. 
We then performed electromyography to measure the nerve conduction velocity. In all 3 affected dogs, 
appendicular and axial skeletal muscles were examined. There was a dense pattern of fibrillation potentials 
and complex repetitive discharges in all tested myotomes. The nerve conduction velocity in the tibial nerves 
was within normal limits along the entire course of the nerve. 
All 3 affected dogs were euthanized at 5 months of age after histological diagnosis (see below) and due to 
the severity of their clinical signs. The three clinically unaffected littermates were examined by means of a 
physical and neurological examination and routine hematology and biochemical profile. No clinical 
abnormalities were detected and results of laboratory testing including CK were normal. The dam and one 
unaffected female sibling were screened for subclinical evidence of the disease by EMG examination and 
muscular biopsy with both tests yielding negative results. 
Similar clinical findings were reported by the owners and their veterinarians in another litter of Landseer 
dogs with two affected siblings (Video S1). These dogs were euthanized at 8 and 15 months of age due to 
severe progressive muscle wasting. 
 
Pathological findings 
We investigated the histopathology of skeletal muscle samples. All affected dogs showed pathological 
variation in muscle fiber size and most of the fibers were round to anisomorphic instead of having a 
(physiological) polygonal shape. Many small fibres were scattered throughout the biopsies, along with some 
hypercontracted fibres. Sporadically invading phagocytes grouped around degenerating fibers. Staining for 
acidic phosphatase showed an increase of activity, indicating degeneration to necrosis in a large number of 
fibres. Some biopsies correlated to an advanced stage of disease with distinct proliferation of the endomysial 
connective tissue and an increase of adipose tissue. These findings demonstrate different stages of muscular 
destruction with compensatory hypertrophy and replacement of lost fibers by connective tissue and fat cells. 
The histhopathological findings were typical for a muscular dystrophy. However, relatively normal 
immunohistochemistry findings with an anti-dystrophin antibody clearly showed that the muscular 
dystrophy in the Landseer dogs is different from the Duchenne/Becker type. The unaffected littermates did 
not show any histopathological alterations (Fig. 1). 
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Fig. 1. Skeletal muscle pathology. (A) M. quadriceps of a 4 months old healthy Landseer dog with normal 
muscle texture without signs of significant pathological changes. Especially, muscle and fiber size 
configuration and variation, sarcolemma, nuclear structure and distribution as well as endomysial connective 
tissue are of physiological appearance. HE-staining, 100x. (B) Same muscle in the Gomori-Trichrome-
staining according to Engel. Normal muscle tissue and fiber structure without considerable pathological 
changes are obvious, especially intrasarcoplasmal texture, mitochondria, muscular nuclei and endomysial 
connective tissue are unobtrusive. (C) M. quadriceps of an affected full-sibling of the control dog shown 
above. HE staining, 100x. The muscle texture is severely disturbed showing a pathological muscle fiber 
variation in size and configuration, signs of de- and regeneration, e.g. nuclear proliferation and distribution, 
as well as a remarkable increase and distortion of the endomysial connective tissue. (D) Same muscle in the 
Gomori-Trichrome-staining according to Engel points up the pathological muscle changes. Interestingly and 
in contrast to other forms of muscle dystrophy such as the Duchenne/Becker analogous disease in Golden 
Retrievers, the sarcoplasm structures and the mitochondria are not markedly altered. (E) 
Immunohistochemistry with an antibody against dystrophin performed on the same muscle as in (C) and 
(D). The diseased muscle shows no deficiency and regular expression of dystrophin. Thus this particular 
muscular dystrophy is markedly different from the Duchenne/Becker types of muscular dystrophy, where 
dystrophin expression is altered. 
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Genetic mapping of the causative mutation 
The pedigrees of the two Landseer families were consistent with a monogenic autosomal recessive mode of 
inheritance. The two litters had a common great-great-grand mother in their maternal lineages. On their 
paternal ancestry we could not detect common ancestors within five generations. 
At the time of the initial mapping of the causative locus we had samples from only four reliably diagnosed 
cases: Three affected littermates from the first family and one isolated case from the second family. We 
additionally had samples from the three non-affected siblings and both non-affected parents of the first 
family. We obtained 173,662 SNP chip genotypes for each of these 9 dogs. We then performed a parametric 
linkage analysis using a fully penetrant, monogenic autosomal recessive model of inheritance in the family 
with its 10 informative meioses. We obtained positive LOD scores for 5 genome segments containing 74 
Mb in total. The highest LOD scores with 1.6 were obtained on chromosomes 24 and 31 (Table S1). 
Based on the pedigree records and typical dog breeding practices we hypothesized that all affected dogs 
most likely were inbred to one single founder animal. Under this scenario the affected individuals were 
expected to be identical by descent (IBD) for the causative mutation and flanking chromosomal segments. 
We therefore analyzed the 4 available cases for extended regions of homozygosity with simultaneous allele 
sharing and found 18 genome regions with a total of 67 Mb that fulfilled our homozygosity search criteria 
(Table S2). 
When we intersected the linked intervals from the family and the homozygous intervals from the four cases, 
only two intervals on chromosomes 10 and 31 remained. Taken together these two intervals had a size of 
4.8 Mb and were considered the minimal critical interval for the subsequent analyses (Fig. 2). 
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Fig. 2. Mapping strategy. (A) A family comprising 6 offspring with their parents and one isolated case 
were available for the initial mapping of the disease locus. We performed parametric linkage analysis for a 
recessive trait in the family and homozygosity analysis across the four cases. (B) The analyses yielded 5 
linked genome segments (orange) and 18 homozygous genome segments (red). Only two regions on 
chromosomes 10 and 31 showed both linkage and homozygosity and were considered the critical intervals 
(arrows). Specifically, these regions corresponded to Chr10:61,871,450-66,047,210 and Chr31:38,752,158-
39,364,930. 
 
 
 
Mutation identification 
In order to obtain a comprehensive overview of all variants in the critical intervals we re-sequenced the 
whole genome of one affected Landseer. We collected 330 million 2 x 100 bp paired-end reads 
corresponding to 14.2x coverage of the genome. We called SNPs and indel variants with respect to the 
reference genome of a presumably non-affected Boxer. Across the entire genome, we detected ~5.6 million 
variants of which ~2.8 million were homozygous variants (Table 1). Within the critical intervals there were 
10,190 variants, of which 38 were predicted to be non-synonymous. 
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Table 1. Variants detected by whole genome re-sequencing of an affected Landseer. 
 
Filtering step Number of variants 
Variants in the whole genomea 2,808,714 
Variants in the critical intervals on CFA 10 and 31      10,190 
Variants in the critical intervals that were absent from 170 other dog genomes             18 
  
Non-synonymous variants in the whole genomea      11,798 
Non-synonymous variants critical intervals on CFA 10 and 31             38 
Non-synonymous variants in the critical intervals that were absent from 170 other dog genomes               1 
a The sequences were compared to the reference genome (CanFam 3.1) from a Boxer. Only variants that were homozygous in the 
affected Landseer are reported. 
 
 
We further compared the genotypes of the affected Landseer with 170 dog genomes of various breeds that 
had been sequenced in the course of other ongoing studies. We hypothesized that the mutant allele at the 
causative variant should be completely absent from all other dog breeds in our sample set. After this filtering 
step only a single non-synonymous private variant remained in the critical intervals, Chr31:39,303,964G>T 
or COL6A1:c.289G>T. We confirmed this variant by Sanger sequencing (Fig. 3) and genotyped it in 58 
Landseer dogs, 404 Newfoundland dogs, and 473 dogs of 63 diverse other breeds. The genotypes showed 
perfect co-segregation with the muscular dystrophy in Landseer dogs and we did not find the variant allele 
outside of the Landseer breed (Table 2; Table S3). The COL6A1:c.289G>T variant represents a nonsense 
mutation in exon 3 of the COL6A1 gene, encoding the alpha-1 chain of collagen type VI. The variant leads 
to an early premature stop codon and is predicted to truncate more than 90% from the COL6A1 open reading 
frame (p.E97*). 
 
 
 
Fig. 3. Electropherograms of the COL6A1:c.289G>T variant. A fragment harboring exon 3 and flanking 
sequences of the COL6A1 gene was PCR-amplified and sequenced with the Sanger method. The figure 
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shows representative traces from Landseer dogs with the 3 different genotypes. The position of the variant is 
indicated by an arrow. 
Table 2. Association of the COL6A1:c.289G>T genotypes with muscular dystrophy. 
 
Genotype Landseer 
casesa 
Landseer 
controlsb 
Newfoundland 
Dogsc 
Control dogs from 
other breedsd 
     
COL6A1:c.289G>T     
       G/G - 33 404 473 
       G/T - 20 - - 
       T/T 5 - - - 
a Four cases had been available at the beginning of the project. A fifth case, full sister to the case from the second family, became 
available only after the genetic mapping of the locus had already been completed. 
b The Landseer controls consisted of 5 close relatives of the affected dogs and 48 Landseer dogs without known relationships to the 
two families with muscular dystrophy. Of these 48 dogs, 33 were homozygous G/G and 15 were heterozygous G/T. In this small and 
not necessarily representative cohort, the carrier frequency was thus 31%. 
c We genotyped a large number of Newfoundland Dogs as the Landseer breed was originally derived from Newfoundland Dogs. The 
404 genotyped samples were collected in the course of other ongoing research projects. 
d These 473 dogs were specifically genotyped for the COL6A1:c.289G>T variant. The genome sequences of 170 independent 
control dogs were also homozygous G/G at this variant. Therefore, the total number of control dogs adds up to 643. 
 
 
 
 
Discussion 
In this study we describe a novel canine muscular dystrophy in Landseer dogs. The clinical and 
histhopathological findings were similar to the severe Duchenne muscular dystrophy in Golden Retrievers 
with a genetic defect in the X-linked DMD gene encoding dystrophin (Cooper et al. 1988; Valentine et al. 
1988; Valentine et al. 1992). However, as male and female Landseer dogs were equally affected in the two 
studied families, an X-linked genetic defect seemed very unlikely. We therefore applied a positional cloning 
approach to elucidate the causative genetic defect. With only one complete family and one additional case 
we were able to map the disease locus to just 0.2% of the dog genome. The increasing availability of 
“personal genomes” in canine genetics allowed us to quickly identify the only non-synonymous genetic 
variant in the critical genome regions that was exclusively present in an affected Landseer and absent from 
170 control dogs. We observed perfect concordance of the genotypes at this variant with the muscular 
dystrophy phenotype in more than one thousand dogs. We have to caution here that our genetic data do not 
prove the causality of the identified variant. Based on these data we cannot formally rule out the possibility 
that the true causative variant is a non-coding regulatory variant or that the true causative variant was 
entirely missed by the chosen short read re-sequencing methodology in combination with an incomplete 
reference genome. 
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On the other hand, the genetic evidence provides statistical support for the causality of the 
COL6A1:c.289G>T for the observed muscular dystrophy. In addition to the genetic data, the functional 
knowledge on collagen type VI from other species is fully consistent with this hypothesis. COL6A1 is 
actually a very good functional candidate gene for a muscular dystrophy as genetic variants in this gene 
cause different human myopathies with variable clinical phenotypes ranging from the milder Bethlem 
myopathy to the severe Ullrich congenital muscular dystrophy. 
The reported variant in Landseer dogs introduces an early stop codon into the open reading frame. Although 
we have not experimentally analyzed the expression of the mutant COL6A1 gene, it seems likely that the 
mutant transcripts will be subject to nonsense-mediated decay and that the COL6A1:c.289G>T variant leads 
to a true null allele of the COL6A1 gene. Unfortunately, we had very limited material from the muscle 
biopsies and could not analyze the RNA experimentally to confirm this hypothesis. 
Based on the combination of the available genetic data, knowledge on COL6A1 function in other species, 
and the fact that the identified nonsense variant is likely to represent a full null allele, we think that the 
causality of the COL6A1:c.289G>T variant for the observed muscular dystrophy has been established 
beyond reasonable doubt. 
In humans with collagen VI alterations, the clinical severity is variable. Ullrich’s congenital muscular 
dystrophy is the most severe phenotype with severe weakness and axial und proximal contractures. Affected 
patients lose the ability to walk within the first or second decade of life. Bethlem congenital muscular 
dystrophy has milder clinical signs including moderate to mild muscle weakness and distal contractures 
only. Between Ullrich’s and Bethlem muscular dystrophies intermediate phenotypes exist with lesser 
degrees of weakness and longer periods of unassisted ambulation (Bönnemann 2011). The Landseer dogs 
showed a severe clinical phenotype, which closely resembles human patients with Ullrich congenital 
muscular dystrophy. The clinical phenotype of these Landseers was more severe than that seen in a 
myopathic Labrador Retriever suspected to also have a defect in collagen VI (Marioni-Henry et al. 2014). 
So far, according to our knowledge, no human patients carrying two truncated COL6A1 alleles have been 
reported. However, it seems plausible that homozygosity for a COL6A1 nonsense variant in the Landseer 
dogs leads to a very severe phenotype with a recessive mode of inheritance. A comparable situation 
resulting in severe clinical phenotypes has been reported in human patients carrying truncating variants on 
both alleles of the COL6A2 gene (Camacho Vanegas et al. 2001; Allamand et al. 2011).  
It is interesting to note that homozygous Col6a1-/- knock out mice show a very mild phenotype that has been 
compared to human Bethlem myopathy although these mice do not express any residual collagen alpha1(VI) 
chains (Bonaldo et al. 1998; Irwin et al. 2003). This is in contrast to humans and dogs where the complete 
COL6A1 deficiency leads to a much more severe phenotype. The comparatively mild murine phenotype 
recapitulates the findings from Duchenne muscular dystrophy: Completely DMD deficient humans and dogs 
suffer from a very severe clinical phenotype, whereas Dmd deficient mice only have a very mild phenotype 
(McGreevy et al. 2015). Thus, the Landseer dogs with the COL6A1:c.289G>T variant are potentially an 
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interesting animal model for human Ullrich congenital muscular dystrophy as they resemble the severe 
human clinical phenotype much closer than Col6a1-/- knock out mice. 
In conclusion, we provide the first comprehensive description of a clinically severe canine muscular 
dystrophy, most likely caused by a nonsense variant in the COL6A1 gene. The affected dogs represent a 
model for human Ullrich congenital muscular dystrophy. Our findings enable genetic testing in dogs, so that 
the non-intentional breeding of affected Landseers can be avoided in the future. 
 
 
Materials and Methods 
 
Ethics statement 
All animal experiments were performed according to the local regulations. The dogs in this study were 
examined with the consent of their owners. The collection of blood samples was approved by the “Cantonal 
Committee For Animal Experiments” (Canton of Bern; permit 23/10). The clinical examinations of affected 
Landseer dogs and their littermates including the collection of muscle biopsies was performed in the course 
of standard veterinary diagnostics, with the consent and on behalf of the dogs’ owners. The clinical 
examinations therefore did not constitute an animal experiment in the legal sense and did not require ethical 
approval. 
 
Clinical examinations 
Three affected Landseer siblings were brought to the neurology service at the Vetsuisse Faculty of Zurich 
for examination and diagnostic testing. A history of all dogs was collected from the breeder. All dogs of the 
litter underwent both a general physical examination and a detailed neurologic examination, as well as 
having complete blood counts, serum biochemistry panels and urinalysis. Electromyography and motor 
nerve conduction velocity (MNCV) were performed on an electrodiagnostic device (Neuroscreen, Toennies 
AG, Germany) with concentric and monoaxial needle electrodes while the animals were maintained under 
general gaseous anesthesia. For MNCV the tibial nerve was examined along its entire course using 
stimulation sites at the trochanteric fossa, the popliteal fossa with recording at the interosseous muscle. 
Muscle biopsies from M. triceps, M. biceps femoris, and M. tibialis cranialis were collected after 
electrodiagnostic testing using an open standard surgical approach. Biopsies were placed in a container 
without any additives and were submitted for histopathologic assessment by overnight express to the 
Institute of Neuropathology of the Heinrich-Heine-University, Düsseldorf (Germany). Clinical data on two 
affected Landseer dogs from a second family was kindly contributed by their owners and the attending 
veterinarians. 
 
Histopathological examinations 
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Muscle biopsies were frozen at -135 °C in isopentan and stored at -80 °C for further analysis. The frozen 
biopsies were cut using a cryosat (CM 1900, Leica Biosystems, Germany) into sections of 7 µm thickness 
and stained using haematoxylin and eosin (HE), modified Gomori trichrome (Engel) and acidic phosphatase 
(AP). All sections were examined under a transmitted light microscope (Orthoplan, Leica Microsystems, 
Germany) in 100x, 400x and 1000x magnification. Additional cryosections were used for 
immunohistochemical stainings using an antibody against the rod domain of dystrophin (1:100, NCL-DYS1, 
Novocastra Laboratory). 
 
Animal selection for the genetic analysis 
This study describes findings from 2 Landseer families. The first family (Fig. 2 A) consisted of the parents 
and 6 offspring that were available for EDTA blood sample collection. A seventh offspring was affected by 
muscular dystrophy, but was euthanized before samples could be taken. From the second family we had 
access to the blood samples of 2 affected female offspring. The sample of the second affected dog from this 
family became available only after we had already completed the initial genetic mapping of the disease 
locus. Thus, in total we had samples from 5 affected Landseer dogs, 3 non-affected full-siblings and 2 non-
affected parents. 
We additionally had samples from 48 other Landseer dogs without known relationships to the two families 
that had been donated to the biobank of the Institute of Genetics. Finally, we also used 404 samples from 
Newfoundland dogs and 473 samples from 63 various diverse dog breeds, which are listed in detail in 
Table S3. 
 
DNA samples and SNP genotyping 
We isolated genomic DNA from EDTA blood samples with the Nucleon Bacc2 kit (GE Healthcare). 
Genotyping was done on illumina canine_HD chips containing 173,662 SNPs by GeneSeek/Neogen. 
Genotypes were stored in a BC/Gene database version 3.5 (BC/Platforms). 
 
Linkage and homozygosity mapping 
For the linkage analysis we had illumina canine_HD SNP chip genotypes from a single family consisting of 
8 animals in total. This family comprised both non-affected parents and six offspring, of which three were 
affected. We used the Merlin software (Abecasis et al. 2002) and a fully penetrant, recessive model of 
inheritance to analyze the data for parametric linkage. 
We used PLINK v1.07 (Purcell et al. 2007) to search for extended intervals of homozygosity with shared 
alleles as described (Drögemüller et al. 2009). The final critical intervals were defined by visual inspection 
of all SNP chip genotypes of the four genotyped cases on chromosomes 10 and 31 in an Excel-file. 
 
Gene analysis 
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We used the dog CanFam 3.1 assembly for all analyses. All numbering within the canine COL6A1 gene 
corresponds to the accessions XM_003434001.3 (mRNA) and XP_003434049.2 (protein). 
 
Whole genome sequencing of an affected Landseer dog 
We prepared a PCR-free fragment library with 300 bp insert size and collected 330,331,465 illumina 
HiSeq2500 paired-end reads (2 x 100 bp) or roughly 14.2x coverage. We mapped the reads to the dog 
reference genome using the Burrows-Wheeler Aligner (BWA) version 0.5.9-r16 (Li and Durbin 2009) with 
default settings and obtained 380,485,021 uniquely mapping reads. After sorting the mapped reads by the 
coordinates of the sequence with Picard tools, we labeled the PCR duplicates also with Picard tools 
(http://sourceforge.net/projects/picard/). We used the Genome Analysis Tool Kit (GATK version v2.3-6, 
(McKenna et al. 2010)) to perform local realignment and to produce a cleaned BAM file. Variant calls were 
then made with the unified genotyper module of GATK. Variant data for each sample were obtained in 
variant call format (version 4.0) as raw calls for all samples and sites flagged using the variant filtration 
module of GATK. Variant calls that failed to pass the following filters were labeled accordingly in the call 
set: (i) Hard to Validate MQ0 ≥ 4 & ((MQ0 / (1.0 * DP)) > 0.1); (ii) strand bias (low Quality scores) QUAL 
< 30.0 || (Quality by depth) QD < 5.0 || (homopolymer runs) HRun > 5 || (strand bias) SB > 0.00; (iii) SNP 
cluster window size 10. The snpEFF software (Cingolani et al. 2012) together with the CanFam 3.1 
annotation was used to predict the functional effects of detected variants. We considered the following 
snpEFF categories of variants as non-synonymous: NON_SYNONYMOUS_CODING, 
CODON_DELETION, CODON_INSERTION, CODON_CHANGE_PLUS_CODON_DELETION, 
CODON_CHANGE_PLUS_CODON_INSERTION, FRAME_SHIFT, EXON_DELETED, 
START_GAINED, START_LOST, STOP_GAINED, STOP_LOST, SPLICE_SITE_ACCEPTOR, 
SPLICE_SITE_DONOR. The critical intervals contained 4,788,534 total and 50,649 coding nucleotides, 
respectively. In our re-sequencing data, we had ≥4x coverage on 4,671,977 bp of the critical interval 
(97.6%) and on 49,327 (97.4%) of the coding bases. The genome sequencing data were deposited in the 
European Nucleotide Archive (ENA) under accession PRJEB9437. 
 
Sanger sequencing 
We used Sanger sequencing to confirm the illumina sequencing results and to perform targeted genotyping 
for selected variants. For these experiments we amplified PCR products using AmpliTaqGold360Mastermix 
(Applied Biosystems). PCR products were directly sequenced on an ABI 3730 capillary sequencer (Applied 
Biosystems) after treatment with exonuclease I and shrimp alkaline phosphatase. We analyzed the Sanger 
sequence data with Sequencher 5.1 (GeneCodes). 
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Table S1. Genome regions that showed positive LOD scores for linkage to muscular dystrophy in a 
family with 10 informative meioses. 
 
Table S2. Homozygous genome regions with shared alleles among the 4 analyzed cases. 
 
Table S3. COL6A1:c.289G>T genotypes of 473 dogs from diverse dog breeds. 
 
Video S1. Clinical phenotype of a 4 month old affected Landseer. 
